<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467920</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-14-10352</org_study_id>
    <nct_id>NCT02467920</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM</brief_title>
  <official_title>Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Switching Premix Human Insulin to Aspart30 in T2DM With Inadequate Glycaemic Control on Premixed Human Insulin and Metformin: a Randomized, Open, Parallel Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of Basal Insulin Glargine Combination with Exenatide bid vs Switching&#xD;
      Premix Human Insulin to Aspart30 in T2DM with Inadequate Glycaemic Control on Premixed Human&#xD;
      Insulin and Metformin: a Randomized, Open, Parallel trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre, open-label, randomized and parallel trial that will compare the&#xD;
      efficacy and safety of basal insulin glargine combination with Exenatide bid vs. switching&#xD;
      premix human insulin to aspart30 in type 2 diabetic patients with inadequate glycaemic&#xD;
      control on premixed human insulin and metformin. Approximately 248 patients will be enrolled&#xD;
      in the study from China and randomized in a 1:1 ratio to one of the 2 treatment arms:&#xD;
      once-daily insulin glargine + twice-daily exenatide + metformin; or twice-daily aspart 30 +&#xD;
      metformin.&#xD;
&#xD;
      Study treatment will continue for 24 weeks. The primary efficacy measure is the change in&#xD;
      HbA1c at 24 weeks. The study consists of 3 periods: a 1-week screening (period A), a 12-week&#xD;
      run-in period (period B) and a 24-week treatment period (period C).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the absolute change in HbA1c from baseline to 24-week endpoint of basal insulin glargine combination with exenatide bid vs. switching to aspart30 in type 2 diabetic patients inadequately controlled on premixed human insulin and metformin.</measure>
    <time_frame>from baseline to 24-week endpoint</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline to 12 weeks endpoint</measure>
    <time_frame>from baseline to 12 weeks endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants who achieved HbA1c ≤ 6.5% and &lt; 7%</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily insulin use</measure>
    <time_frame>baseline, 12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>from baseline to 12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and rate of hypoglycaemic events during the study</measure>
    <time_frame>baseline, 12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">349</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>glargine + exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspart 30</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to aspart 30 ( subcutaneous injection, twice daily).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glargine + exenatide</intervention_name>
    <description>glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily)</description>
    <arm_group_label>glargine + exenatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspart 30</intervention_name>
    <description>aspart 30 ( subcutaneous injection, twice daily)</description>
    <arm_group_label>aspart 30</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of informed consent&#xD;
&#xD;
          -  Type 2 diabetic patients receiving twice-daily premixed human insulin 30 therapy ≥ 30&#xD;
             U/d and metformin with maximum tolerated dosage (≤ 1500mg/d)&#xD;
&#xD;
          -  HbA1c &gt; 8.0 % and &lt; 11.0 % (HbA1c &gt; 7.0 % and &lt; 10.0% at randomization)&#xD;
&#xD;
          -  Men and women (non-pregnant and using a medically approved birth-control method) aged&#xD;
             ≥ 18 and ≤ 70 years&#xD;
&#xD;
          -  BMI ≥ 23 and ≤ 35 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes or other specific types of diabetes&#xD;
&#xD;
          -  Pregnancy, preparation for pregnancy, lactation and women of child-bearing age&#xD;
             incapable of effective contraception methods&#xD;
&#xD;
          -  Uncooperative subject because of various reasons&#xD;
&#xD;
          -  Abnormal liver function, glutamic-pyruvic transaminase (ALT) and glutamic-oxaloacetic&#xD;
             transaminase (AST) &gt; twice the upper limits of normal&#xD;
&#xD;
          -  Impairment of renal function, serum creatinine: ≥ 133mmol/L for female，≥ 135mmol/L for&#xD;
             male&#xD;
&#xD;
          -  Serious chronic gastrointestinal diseases&#xD;
&#xD;
          -  Edema&#xD;
&#xD;
          -  Serious heart diseases, such as cardiac insufficiency (level III or more according to&#xD;
             NYHA), acute coronary syndrome and old myocardial infraction&#xD;
&#xD;
          -  Blood pressure: Systolic blood pressure (SBP) ≥ 180mmHg and/or diastolic blood&#xD;
             pressure (DBP) ≥ 110mmHg&#xD;
&#xD;
          -  White blood count (WBC) &lt; 4.0×109/L or platelet count (PLT) &lt; 90×109/L，or definite&#xD;
             anemia (Hb：&lt; 120g/L for male, &lt; 110g/L for female), or other hematological diseases&#xD;
&#xD;
          -  Endocrine system diseases, such as hyperthyroidism and hypercortisolism&#xD;
&#xD;
          -  Experimental drug allergy or frequent hypoglycemia&#xD;
&#xD;
          -  Psychiatric disorders, drug or other substance abuse&#xD;
&#xD;
          -  Diabetic ketoacidosis and hyperosmolar nonketotic coma requiring insulin therapy&#xD;
&#xD;
          -  Stressful situations such as surgery, serious trauma and so on&#xD;
&#xD;
          -  Chronic hypoxic diseases such as pulmonary emphysema and pulmonary heart disease&#xD;
&#xD;
          -  Combined use of drugs effecting glucose metabolism such as glucocorticoid&#xD;
&#xD;
          -  Tumor, especially bladder tumor and/or family history of bladder tumor and/or&#xD;
             long-term hematuria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science and technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>November 12, 2018</last_update_submitted>
  <last_update_submitted_qc>November 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xuefeng Yu</investigator_full_name>
    <investigator_title>Director of Department of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>exenatide</keyword>
  <keyword>glargine</keyword>
  <keyword>aspart 30</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

